BC-2048 (P-12): sc-83516



The Power to Question

BACKGROUND

The smallest of the human chromosomes, 21 makes up about 1.5% of the human genome. Chromosome 21 contains nearly 300 genes and 47 million base pairs. Down syndrome, also known as trisomy 21, is the disease most commonly associated with chromosome 21. Alzheimer's disease, Jervell and Lange-Nielsen syndrome and amyotrophic lateral sclerosis are also associated with chromosome 21. Translocations are found to occur between chromosome 21 and 8, and chromosome 21 and 12 in certain leukemias. BC-2048, also known as C21orf114, is a 209 amino acid protein that belongs to the transposase 22 family.

REFERENCES

- 1. Tesson, F., Donger, C., Denjoy, I., Berthet, M., Bennaceur, M., Petit, C., Coumel, P., Schwarts, K. and Guicheney, P. 1996. Exclusion of KCNE1 (IsK) as a candidate gene for Jervell and Lange-Nielsen syndrome. J. Mol. Cell. Cardiol. 28: 2051-2055.
- Tyson, J., Tranebjaerg, L., Bellman, S., Wren, C., Taylor, J.F., Bathen, J., Aslaksen, B., Sørland, S.J., Lund, O., Malcolm, S., Pembrey, M., Bhattacharya, S. and Bitner-Glindzicz, M. 1997. lsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum. Mol. Genet. 6: 2179-2185.
- Müller, S., Stanyon, R., Finelli, P., Archidiacono, N. and Wienberg, J. 2000. Molecular cytogenetic dissection of human chromosomes 3 and 21 evolution. Proc. Natl. Acad. Sci. USA 97: 206-211.
- Mao, R., Wang, X., Spitznagel, E.L., Jr., Frelin, L.P., Ting, J.C., Ding, H., Kim, J.W., Ruczinski, I., Downey, T.J. and Pevsner, J. 2005. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol. 6: 107.
- Robakis, N.K. 2006. The discovery and mapping to chromosome 21 of the Alzheimer's amyloid gene: history revised. J. Alzheimers Dis. 10: 453-455.
- Sun, X., He, G. and Song, W. 2006. BACE2, as a novel APP θ-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J. 20: 1369-1376.

SOURCE

BC-2048 (P-12) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping within an internal region of BC-2048 of human origin.

PRODUCT

Each vial contains 100 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-83516 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

BC-2048 (P-12) is recommended for detection of BC-2048 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for BC-2048 siRNA (h): sc-91422, BC-2048 shRNA Plasmid (h): sc-91422-SH and BC-2048 shRNA (h) Lentiviral Particles: sc-91422-V.

Molecular Weight of BC-2048: 24 kDa.

Positive Controls: BJAB-2 whole cell lysate or Raji whole cell lysate.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com